Source of this article: Times Finance Author: Li Aohua
"Gloves" Inke Medical The actual controller has greatly reduced its holdings, and 50,000 shareholders have sleepless nights.
Image source: pexels
On the evening of June 1, Inke Medical announced that due to personal capital needs, company actual controller and chairman Liu Fangyi plans to 2021 June 24-December 24 on June 24 Within a month, directly reduce the company's shares by means of centralized auction trading , block trading not more than 21.7555 million shares, that is, not more than 6% of the company's total share capital . In addition, Chen Qiong, general manager of Yingke Medical, Yu Haisheng, deputy general manager, Li Bin, deputy general manager, and Feng Jie, director of finance, plan to reduce the company's shares by 0.02%, 0.01%, 0.02% and 0.01% respectively.
If calculated based on the closing price of on June 1, , Liu Fangyi and the senior executives of Inke Medical have reduced their holdings and cashed out a total of more than 3 billion yuan.
"I think everyone underestimates the importance of the industry (medical gloves) in China." Liu Fangyi's argument that he is optimistic about the medical glove track is still in his ears, and the huge reduction in holdings has already caught investors by surprise. According to the first quarterly report, the number of shareholders of Yingke Medical is 50,000.
On June 2, Inke Medical opened sharply lower by 317.2%, and then fell by the limit. As of the close, Inke Medical reported 114.12 yuan per share, fell 320%, and the total market value evaporated over 10.3 billion yuan in one day.
Image source: Snowball
Inke Medical Dragon Tiger List data shows that Shenzhen Stock Connect sold 232 million yuan, and bought 53.75 million, and the three institutions sold a total of 643 million yuan. Orient Fortune Securities Lhasa Tuanjie Road Second Securities Branch bought 130 million yuan.
In addition, Inke Medical also "brought down" the medical device section by itself.
and Yingke Medical , Lansail Medical (002382.SZ) and Zhonghong Medical (300981.SZ), which are also known as the "Three Gloves", fell 4.51% and 4.55% respectively today.
Flush data shows that the medical device sector fell by 3.27% today, Yingke Medical led the decline with a 20% decline, Haohai Biological Technology Taixinguang (688677.SH) and Aibo Medical (688050.SH) both fell by more than 10%.
The left-hand package will increase steadily, and the right-hand will significantly reduce
Since its establishment in 2009, Inke Medical has been working in the medical glove manufacturing industry for more than 10 years. Performance has been uneventful.
But after the outbreak of the new crown pneumonia epidemic, the share price of Inke Medical skyrocketed 14 times in 2020, all the way from about 11 yuan/share to 168 yuan/share. In January 2021, the stock price of Inke Medical once reached 294.11 yuan per share, a record high, and its market value exceeded 100 billion yuan.
"2020 is a highlight moment for and , and it is also a new starting point." said Liu Fangyi.
but Inco Medical 's highlight moment is fleeting. Since February this year, Yingke Medical has plummeted. As of today's close, the stock price of Yingke Medical has fallen by more than 60% from its historical high, and the stock price is "ankle cut".
During the continuous decline of of Inke Medical, some angry investors left messages under Liu Fangyi's personal Weibo. Liu Fangyi replied on Weibo on March 24: "Will the stock price affect the mood? Yes. Will the stock price hinder the development of Inke Medical ? No!" Here, Liu Fangyi also performed a "God Operation".
On November 17, 2020, Inke Medical disclosed a "Report on Changes in New Shares and Listing Announcement on Issuance of Shares to Specific Objects", and planned to issue 17.4155 million shares at a price of 28.71 yuan per share. More than 500 million yuan, after deducting issuance expenses, will be used for "annual production of 6.18 billion (6.18 million boxes) of high-end medical gloves" and supplementary liquidity.
Liu Fangyi took the fixed increase shares by himself, and the lock-up period was 36 months. On the day of issuance (November 17, 2020), the closing price of Inke Medical was 103.7 yuan per share, which also means that on the first day of the fixed increase, Liu Fangyi's floating profit has exceeded 1.3 billion yuan. Just 6 months after
monopolized the fixed increase, Liu Fangyi lowered his original holdings of 21.7555 million shares in a high-profile manner, arousing the dissatisfaction of many investors.
In the stock bar of Yingke Medical , some investors said that "the chairman's appearance is too ugly", "as a boss, you can't think about making the price difference of shareholders on the stock market " "Boss Liu's bomb is too cruel".
However, this reduction of Liu Fangyi's holdings is not without warning. On August 16, 2019, Inke Medical publicly issued convertible bonds . Since then, Liu Fangyi has frequently reduced his holdings and bought convertible bonds.
On April 27, Yingke Medical announced that the controlling shareholder Liu Fangyi reduced its holdings of Yingke convertible bonds by a total of 470,000 from September 26, 2019 to April 27, 2021, accounting for 10% of the total issuance. %.
In 2020, Liu Fangyi also received a regulatory letter from the China Securities Regulatory Commission for short-term trading of Yingke convertible bonds. The regulatory letter shows that during the period from March 5 to 12, 2020, Liu Fangyi sold about 420,000 Yingke convertible bonds in total, with a reduction of 135 million yuan, and bought Yingke convertible bonds on March 10 and 11 respectively. 6,000 copies and 12,500 copies, with purchase amounts of 1,995,500 yuan and 4,153,400 yuan respectively, which constitute short-term transactions stipulated in Article 44 of the " Securities Law ".
On June 2, Times Finance and Economics called the securities department of Inke Medical several times, but no one answered.
Has the high growth of Intech come to an end?
The COVID-19 outbreak has boosted the sales of medical PVC gloves and nitrile gloves , and the performance of Inke Medical also ushered in an outbreak in 2020.
According to the financial report, in 2020, Inke Medical achieved revenue of 13.837 billion yuan, increased by over 560% year-on-year, and achieved a net profit of 7.007 billion yuan, a year-on-year increase of 3829.56%. In the first quarter of 2021, Inke Medical 's revenue was 6.735 billion yuan, a year-on-year increase of 770.86%, and a net profit of 3.736 billion yuan, a year-on-year increase of 2791.66%.
But since the beginning of this year, the price of medical gloves has begun to gradually adjust.
According to previous reports from Times Finance, in late January this year, Inke Medical PVC gloves were quoted at about 500 yuan/box (1000 pieces/box), and composite nitrile gloves were quoted at 560 yuan/box.
On June 2nd, Times Finance learned from an Yingke medical agent that the current quotation of Yingke medical PVC gloves is 180 yuan/box (tax included), and the compound nitrile gloves have also dropped to 270 yuan/ box. The above-mentioned agents told Times Finance that the price of medical gloves has been falling after the year.
Inke Medical also admitted in its annual report: "There is a possibility of oversupply in the short-term market. If there is a change in the relationship between supply and demand, the decline in product prices may reduce the company's gross profit margin, which will adversely affect the company's performance."
Guangzhou Zhongcheng Medical Device Industry Senior Researcher Zheng Ke told Times Finance on June 2 that the mold preparation and molding process of the medical glove production line are relatively mature, and the international competition situation is not very optimistic.The core competitiveness of medical gloves lies in the synthesis and performance of raw materials (nitrile latex). However, domestic glove manufacturers such as Lanfan and Inke currently do not have the synthesis technology of core raw materials, so it is difficult to further reduce the processing cost .
However, Inke Medical has already planned to lay out the production of raw materials.
Affected by the epidemic, the supply of nitrile latex raw materials in the upstream market of medical gloves tends to be tight. In order to ensure the normal operation of subsequent production and operation and reduce external risks, on August 4, 2020, the Inke Medical subsidiary established a holding subsidiary In this way, 700 million yuan was invested in the construction of a project with an annual output of 500,000 tons of carboxylated nitrile latex and 100,000 tons of DOTP. The project construction period is expected to be 15 months.
Inke Medical said that from a long-term perspective, this foreign investment in will have a positive effect on the company's future operations, which will help expand the company's business scope and enhance the company's comprehensive strength and overall competitiveness.
"Although the use of medical gloves will decline after the epidemic, as a reserve of emergency epidemic prevention materials in various provinces across the country, the market demand for medical gloves will continue to exist." Zheng Ke said.
According to Zheng Ke's introduction, nitrile gloves have a wide range of applications. In addition to medical applications, semiconductors, precision electronic components, scientific research institutions, biopharmaceuticals, beauty salons, agricultural planting, housework and other fields demand nitrile gloves for nitrile gloves. It is also increasing year by year.
As for the post-epidemic development of Inke Medical , Liu Fangyi once said: "If anyone doubts that Inke Medical 's results in 2020 are 99% luck + 1% effort, we will prove it in the next 5-10 years. , 99% of our success depends on our hard work, wisdom, and 1% luck!"
